Abstract 466P
Background
Checkpoint inhibitors have been regarded as an alternative to docetaxel as the new standard second-line therapy or even first-line therapy in advanced non-small cell lung carcinoma (NSCLC), nevertheless, little is known about the effect of patients’ age on the efficiency of immune checkpoint inhibitors as cancer treatments. Thus, we did a systematic review and meta-analysis to assess the immune checkpoint inhibitor vs docetaxel efficacy in subgroups defined by patients’ age.
Methods
A comprehensive search of online databases was performed. The main purpose was to evaluate the difference in efficacy of immune checkpoint inhibitors between patients above age 65 and under 65, measured in terms of the difference in overall survival log(HR) reported in study participants above and under 65. A random-effects model was used to calculate the pooled overall survival HR and 95% CI in patients above and under 65.
Results
A total of 19 eligible randomized controlled trials of immune checkpoint inhibitors (ipilimumab, tremelimumab, nivolumab, or pembrolizumab) that reported overall survival according to patients’ age were recruited. Overall, the pooled overall survival HR was 0.75 (95% CI 0.67–0.85) (p<0.001) while the pooled progression-free survival HR was 0.72 (95% CI 0.55–0.93) (p = 0.011) in patients under age 65 treated with immune checkpoint inhibitors, compared with patients treated in control groups. In patients above age 65 treated with immune checkpoint inhibitors, the pooled overall survival HR compared with control groups was 0.80 (95% CI 0.74–0.87) (p<0.001) and the pooled progression-free survival HR was 0.81 (95% CI 0.67–0.97) (p = 0.223). The difference in efficacy between patients above and under 65 treated with immune checkpoint inhibitors was significant in overall survival. Nevertheless, there were no significant differences in progression-free survival between groups.
Conclusions
Immune checkpoint inhibitors can improve overall survival for patients with advanced cancers such as non-small-cell lung cancer. However, the magnitude of benefit is age-dependent. Future research should guarantee greater inclusion of patients under age 65 in trials and focus on improving the effectiveness of immunotherapies in patients under age 65.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Thoracic Surgery and Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract